Lee SH, et al. - In order to investigate any possible survival benefit of an early start of palliative chemotherapy in patients with unresectable pancreatic cancer, researchers assessed survival outcome in 838 patients with unresectable pancreatic cancer in relation to time interval between cancer diagnosis and initiation of palliative chemotherapy. These patients were retrospectively enrolled. A time interval between cancer diagnosis and the initiation of palliative chemotherapy of >2 weeks in these patients was not related to a worse survival outcome. If they initially presented with jaundice, patients with a time interval ≤2 weeks exhibited poorer survival outcome vs those with the time interval >2 weeks in subgroup analyses. If they initially presented with pain, patients with a time interval ≤2 weeks had a better survival outcome vs those with the time interval >2 weeks.